Mirati Therapeutics | MRTX - Betriebsaufwand



Betriebsaufwand Veränderung Datum
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Astellas Pharma JPY 489.36B 52.69B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bayer EUR 10.33B 126M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12